Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs EHang Holdings Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while EHang Holdings Ltd - ADR trades at $5.41 (market cap $423.98M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 94.1× EHang Holdings Ltd - ADR's market cap. Which is the better fit depends on your goals.
| ALNY | EH | |
|---|---|---|
Market Cap | $39.89B | $423.98M |
Sector | Health | Industrials |
52-Week High | $491.22 | $19.99 |
52-Week Low | $278.09 | $5.52 |
Enterprise Value | $38.15B | $363.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EHang Holdings (EH) trades at $5.59, down 3.45% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. Despite a high gross margin of 61.53%, net losses persist with a -77.56% margin. Cash flow improved in 2024 but reversed negative in 2025. Recent news highlights volatility, including an 18% surge on June 15, 2026, followed by concerns over Q1 sales missing forecasts.
The outlook remains speculative with significant execution risks amid ongoing losses, though analyst consensus suggests moderate upside to a $6.97 target. Investment opportunity hinges on commercial scaling of eVTOL operations, but high cash burn and competitive pressures pose substantial risks. Sentiment is divided, with 40% sell ratings reflecting skepticism over near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
